Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study - Biogen (NASDAQ:BIIB)

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing rapid and significant reduction in depressive symptoms in a late-stage study.

To add Benzinga News as your preferred source on Google, click here.

The drug, zuranolone, also met the study's secondary goal of showing an improvement in symptoms when administered with a standard of care antidepressant, compared to a combination of placebo and antidepressants over two weeks.
Related: Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients.
Sage plans to start submitting data for U.S. approval of zuranolone for major depressive disorder on a rolling basis early this year and is aiming to complete the application by the second half of the year.
Zuranolone 50 mg co-initiated with a standard of care antidepressant was generally well-tolerated, with most TEAEs reported as mild or moderate and no new safety signals identified.
Price Action: SAGE shares are down 16% at $36.27, BIIB stock is down 0.58% at $216.10 during the market session on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.